ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer - Wikidata - awgldk - TriplyDB

ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer

ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer

http://www.wikidata.org/entity/Q35479617

about

Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions Approaches to modernize the combination drug development paradigm Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer Large-scale quality analysis of published ChIP-seq data.Transcriptional regulation prediction of antiestrogen resistance in breast cancer based on RNA polymerase II binding data.Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence.Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer.Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.Novel Strategies to Improve the Endocrine Therapy of Breast Cancer.HSP90 inhibitor AUY922 can reverse Fulvestrant induced feedback reaction in human breast cancer cells Differences in the transcriptional response to fulvestrant and estrogen deprivation in ER-positive breast cancer Palbociclib: an evidence-based review of its potential in the treatment of breast cancer CDK4 inhibition and doxorubicin mediate breast cancer cell apoptosis through Smad3 and survivin.Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.Modeling time-dependent transcription effects of HER2 oncogene and discovery of a role for E2F2 in breast cancer cell-matrix adhesion Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.The history and future of targeting cyclin-dependent kinases in cancer therapy.Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer.HER2 Signaling Drives DNA Anabolism and Proliferation through SRC-3 Phosphorylation and E2F1-Regulated Genes Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models.Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.Overexpression of E2F mRNAs associated with gastric cancer progression identified by the transcription factor and miRNA co-regulatory network analysis.LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells.PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.Molecular mechanisms regulating the hormone sensitivity of breast cancer.Will PI3K pathway inhibitors be effective as single agents in patients with cancer?Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.Data supporting the structural and functional characterization of Thrombin-Activatable Fibrinolysis Inhibitor in breast cancer Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer.Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus.The genomic landscape of breast cancer as a therapeutic roadmap Palbociclib inhibits epithelial-mesenchymal transition and metastasis in breast cancer via c-Jun/COX-2 signaling pathway.A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.

P2860

Q27022834-2D4C0BC6-AD39-4484-8ACE-20CBC312D276 Q28072074-06E231AE-0178-4597-934D-45C6815BEEA7 Q30408963-6341CBEC-B359-48B1-ABD9-329E19FE958A Q30717456-48FE2BE2-3DB8-4AA6-A29D-5CA71095BF81 Q30763243-8C60E758-68DB-4C0D-B7E4-36ADC1AA6D81 Q33571040-165FBD67-7AE2-4114-BEFB-5078FFA490F0 Q33591690-D64C0CB9-65DB-4EC9-80E4-89FC60CE4FFA Q33614544-C5844366-869D-40D2-8041-25B8C93451B6 Q33660573-525914C0-05E4-4682-A999-5763D3E2F22F Q33727284-68839E21-A399-4117-83DC-5DBB86EAF295 Q33823200-09A3AB22-0280-492C-A867-EA7CEB609A5F Q33993400-8A78FAEB-A24B-455A-85B0-F320624563CF Q34027724-C20A2FE5-285B-4170-8E76-200FE8546362 Q34036076-F055EA49-EC4E-4885-AC7B-31CBC397E419 Q34147910-86B7C286-CB1E-4C5A-B8D8-CD84FFC06D6A Q34360155-8A5BCF78-5981-4FED-90C8-53A53D10E10F Q34394399-50FE7709-CB5C-4702-BB58-7C67666EA3A1 Q34460347-ACA1A31B-C07C-4B20-B6D4-3D9E7155B8D3 Q34461019-613CE535-3FBF-4761-9C5E-22CB0861B81D Q34511826-684FD64D-A98B-44BD-ADDF-75E3AD05E242 Q34619220-B3442504-2AAA-4225-B6B2-5D6FE856AC89 Q34793260-32CE5391-0F32-4BBA-8007-2E1C07330673 Q34979448-45BF43FE-4BAE-47DE-BCAC-1425789DF8B0 Q34995919-3DB04F7D-5320-4C88-9B91-6F7AA26FC253 Q35043503-4BD41E5D-5B1B-4F5C-9950-6F59D72D22C1 Q35145443-E1AD8EB3-FB4A-461E-A186-37C3E2DD92EA Q35168124-5D58AC2C-ACB6-4015-A8DA-A4CB86C873E6 Q35256618-B9F8F4CC-161E-4A84-B843-C605615FBB99 Q35558610-2EE672A8-1B8E-4C61-874E-C5E1DF17A187 Q35610581-186AAE0A-B915-4A08-8E29-63B8FD6DDA38 Q35713360-8453345F-2EA1-4E25-9BF4-47695AD0F2D8 Q35764392-80656D73-D6A9-4A84-98B1-51587280674B Q35861503-674B9B63-5879-409B-A502-BA4517C4A6C0 Q35887881-1923CC26-5713-4B28-895B-FA8D4C9F252B Q36321147-F37EDF92-3987-4B11-BAC5-F13906FA8CA9 Q36485168-75785177-B557-43BA-9F7A-B9E9EBFBA3D5 Q36547566-4DC8A82D-163E-4E92-BA7B-402DEAF42A65 Q36558069-351DE493-3DAA-4B5E-80BB-2A3938B5D5FA Q36561589-A06F4EF6-8174-41A3-8531-749581C059B0 Q36759372-C85E80BB-8A88-4C6B-933B-25E059A54463

P2860

ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer

http://www.wikidata.org/entity/Q35479617

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

ERα-dependent E2F transcriptio ...... ivation in human breast cancer

@ast

ERα-dependent E2F transcriptio ...... ivation in human breast cancer

@en

type

label

ERα-dependent E2F transcriptio ...... ivation in human breast cancer

@ast

ERα-dependent E2F transcriptio ...... ivation in human breast cancer

@en

prefLabel

ERα-dependent E2F transcriptio ...... ivation in human breast cancer

@ast

ERα-dependent E2F transcriptio ...... ivation in human breast cancer

@en

P1433

Q35479617-047F6DDB-8F1E-401C-98A8-BB1753EC2D84

P1476

Q35479617-BEC910A2-D531-47FB-8125-9E0BC31F93A4

P2093

Q35479617-03F80FEC-91BB-4B62-856E-5D1992051776

Q35479617-26EB5C10-7ACA-4830-83AE-8845FE8A659A

Q35479617-28F999F9-63A1-4AF0-83FD-F40AEA0494EA

Q35479617-2FF0BDBA-0F52-4698-A18E-57ED3ABED970

Q35479617-377389B1-A532-465D-A22D-1138047468BA

Q35479617-38D5F5EA-548B-47FA-87B1-5BE0076107A3

Q35479617-450BECBA-7BBD-4AF3-8EC2-85AA22828C60

Q35479617-68636AF3-5894-4DA2-BB5B-A7C6B7BC2EC5

Q35479617-7548BDEA-C7D6-4E0C-B906-50CCDD20EC2D

Q35479617-A637BD39-D93F-4AFF-96E5-1864819BC454

P2860

Q35479617-0433FFD2-5C1D-402F-9C5C-4122A45F56E4

Q35479617-07C51605-45E0-4B41-B3CD-67F1352C1756

Q35479617-0F0FAA87-7AFB-4D7C-8A98-D7923026842F

Q35479617-0FF5A9E6-84BA-497D-801E-4AEA154C30A6

Q35479617-132B8174-A37A-4380-80A4-915AD20CE105

Q35479617-14DB3A54-A84E-4FFB-A513-A43A95A4D456

Q35479617-16BBA223-F7F1-4E65-AF4D-85220B4B6CD9

Q35479617-1A6A53CA-563D-4DCD-9D61-83231DBE0FEE

Q35479617-2A3C2CA7-29D8-4209-8F5C-5E3BFBFE98DE

Q35479617-3F4B79A4-FF7F-47AD-83DF-473174E7B4FD

P304

Q35479617-BE83F427-0C7C-4B19-9ABE-3D2EA1BF42F0

P31

Q35479617-600053F0-DF42-44F0-9420-8ABCB1701883

P356

Q35479617-1BE5AE83-A882-4ED7-9D22-73E3565C0DFB

P433

Q35479617-8A36CD50-D319-466B-BE13-14A97EF5155E

P478

Q35479617-DBF8A145-C12C-4EBC-9137-2D507835F61C

P50

Q35479617-4AD3169E-C7E8-4129-AE8A-495FD0BA5FDB

Q35479617-C845A590-BDA5-426B-8C41-AD3EF33EF3FC

P577

Q35479617-37DB1BAA-A181-45B6-8B4C-41D89483F573

P5875

Q35479617-0920B4A1-68C0-4499-A487-DD591BE0AE38

P698

Q35479617-D8118FA6-87DA-4782-8578-98C345C66C93

P921

Q35479617-A0B24DC1-526D-4C28-8656-A4A81B19C0FD

P932

Q35479617-B9390935-0015-44C4-89F7-A441FCA2BA87

P356

2159-8290.CD-11-0101

P1433

Cancer Discovery

P1476

ERα-dependent E2F transcriptio ...... ivation in human breast cancer

@en

P2093

Aixiang Jiang

http://www.w3.org/2001/XMLSchema#string

Ana M González-Angulo

http://www.w3.org/2001/XMLSchema#string

Anita Dunbier

http://www.w3.org/2001/XMLSchema#string

Carlos L Arteaga

http://www.w3.org/2001/XMLSchema#string

Catherine Higham

http://www.w3.org/2001/XMLSchema#string

Emily M Fox

http://www.w3.org/2001/XMLSchema#string

Gordon B Mills

http://www.w3.org/2001/XMLSchema#string

H Charles Manning

http://www.w3.org/2001/XMLSchema#string

Helen Anderson

http://www.w3.org/2001/XMLSchema#string

Maria G Kuba

http://www.w3.org/2001/XMLSchema#string

P2860

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Gene ontology: tool for the unification of biology

Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer

Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta

Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance

An oestrogen-receptor-α-bound human chromatin interactome

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease

Genome-wide analysis of estrogen receptor binding sites

Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.

PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.

P304

338-351

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2159-8290.CD-11-0101

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Justin M. Balko

P577

2011-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51766286

http://www.w3.org/2001/XMLSchema#string

P698

22049316

http://www.w3.org/2001/XMLSchema#string

P921

P932

3204388

http://www.w3.org/2001/XMLSchema#string